Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis

Next Previous
X
Search
Trial Profile

A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berdazimer sodium (Primary)
  • Indications Atopic dermatitis
  • Focus Biomarker; Pharmacokinetics
  • Sponsors Novan Inc

    • Most Recent Events

    • 11 Dec 2018 According to a Novan media release, data from this trial will be presented at the 3rd Inflammatory Skin Disease Summit in Vienna, Austria.
    • 06 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 20 Aug 2018 According to a Novan media release, data will be submitted for presentation by Drs. Guttman and Maeda-Chubachi at upcoming scientific and medical meetings.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top